Skip to main content
. 2023 Sep 23;4(5):e367. doi: 10.1002/mco2.367

FIGURE 7.

FIGURE 7

Major FGFR‐targeted drugs in tumors. The target drugs of FGFR in tumors are mainly TKIs, among which, futibatinib as a non‐ATP‐competitive inhibitor can directly bind to the P‐loop of kinase domain, while other drugs are ATP kinase inhibitors, in addition, there are also monoclonal antibody drugs and FGF ligand trap.